Protein Nanoparticle-Mediated Delivery of Recombinant Influenza Hemagglutinin Enhances Immunogenicity and Breadth of the Antibody Response

[Image: see text] The vast majority of seasonal influenza vaccines administered each year are derived from virus propagated in eggs using technology that has changed little since the 1930s.

The immunogenicity, durability, and breadth of response would likely benefit from a recombinant nanoparticle-based approach.

Although the E2 protein nanoparticle (NP) platform has been previously shown to promote effective cell-mediated responses to peptide epitopes, it has not yet been reported to deliver whole protein antigens.

In this study, we synthesized a novel maleimido tris-nitrilotriacetic acid (NTA) linker to couple protein hemagglutinin (HA) from H1N1 influenza virus to the E2 NP, and we evaluated the HA-specific antibody responses using protein microarrays.

We found that recombinant H1 protein alone is immunogenic in mice but requires two boosts for IgG to be detected and is strongly IgG1 (Th2) polarized.

When conjugated to E2 NPs, IgG2c is produced leading to a more balanced Th1/Th2 response.

Inclusion of the Toll-like receptor 4 agonist monophosphoryl lipid A (MPLA) significantly enhances the immunogenicity of H1–E2 NPs while retaining the Th1/Th2 balance.

Interestingly, broader homo- and heterosubtypic cross-reactivity is also observed for conjugated H1–E2 with MPLA, compared to unconjugated H1 with or without MPLA.

These results highlight the potential of an NP-based delivery of HA for tuning the immunogenicity, breadth, and Th1/Th2 balance generated by recombinant HA-based vaccination.

Furthermore, the modularity of this protein–protein conjugation strategy may have utility for future vaccine development against other human pathogens.